middle.news
Patrys Abandons PAT-DX1 Trial Plans, Accelerates PAT-DX3 Development
7:03pm on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Patrys Abandons PAT-DX1 Trial Plans, Accelerates PAT-DX3 Development
7:03pm on Monday 2nd of June, 2025 AEST
Key Points
PAT-DX1 drug material fails specification testing, unsuitable for Phase 1 trial
Strategic pivot to develop PAT-DX3 targeting inflammatory diseases via NETosis inhibition
Cost reduction measures implemented to preserve cash reserves
Received $1.3 million R&D tax incentive rebate for FY2023/24
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PAB
OPEN ARTICLE